All In Biotech

Drug Trial Radar · NCT05970978

A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

152

Actual

Start

Aug 28, 2023

Primary completion

Jul 19, 2024

Study completion Jan 26, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label study aim to evaluate the efficacy and safety of IBI112 in Chinese participants with plaque psoriasis who were treated with biologics and switched to IBI112. The study will enroll 160 participants who were diagnosed with plaque psoriasis. The whole study consists of 4 weeks of screening, 32 or 36 weeks of treatment and a safety follow-up visit at Week 44.

Conditions

  • Psoriasis

Interventions

  • regular treatmentDrug

    IBI112 200mg s.c. at week 0, 12, 24 and 36.

  • Intensive treatmentDrug

    IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who achieve sPGA clean (0) or nearly clean (1) ,and BSA < 3%Time frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.